Cytokinetics

FDA kicks off review of Cytokinetics' aficamten for HCM
Pharmaphorum
Tue, 12/3/24 - 09:39 am
Cytokinetics
FDA
aficamten
obstructive hypertrophic cardiomyopathy
Bristol Myers Squibb
Camzyos
Bayer lands regional rights to aficamten in Japan deal with Cytokinetics
First Word Pharma
Tue, 11/19/24 - 11:20 am
Bayer
Japan
Cytokinetics
aficamten
hypertrophic cardiomyopathy
Eyeing drug launch in 2025, Cytokinetics rolls out HCM awareness campaign
Medical Marketing and Media
Sun, 11/10/24 - 09:30 pm
Cytokinetics
hypertrophic cardiomyopathy
aficamten
Investors say 'no bueno' as Cytokinetics stymies M&A prospects with complex Royalty deal
Fierce Biotech
Thu, 05/23/24 - 11:04 am
Cytokinetics
Royalty Pharma
aficamten
Cytokinetics shows hand in high stakes rivalry with BMS' Camzyos
Fierce Biotech
Mon, 05/13/24 - 11:08 am
Cytokinetics
Bristol Myers Squibb
Camzyos
aficamten
heart disease
Amgen Emerges as Potential Cytokinetics Suitor as Novartis Pulls Away: Reports
BioSpace
Fri, 01/12/24 - 09:59 am
Novartis
Cytokinetics
Amgen
M&A
Novartis drops pursuit of Cytokinetics - source
Reuters
Thu, 01/11/24 - 08:41 pm
Novartis
Cytokinetics
M&A
Novartis in advanced talks to buy Cytokinetics
Reuters
Mon, 01/8/24 - 10:29 pm
Novartis
Cytokinetics
M&A
aficamten
2 Biotechs That Could Get Bought Out in 2024
Yahoo/Motley Fool
Wed, 01/3/24 - 04:59 pm
M&A
BridgeBio Pharma
Cytokinetics
Cytokinetics' heart failure drug improves exercise capacity, sending shares soaring in long-awaited win
Fierce Biotech
Wed, 12/27/23 - 11:06 pm
Cytokinetics
cardiomyopathy
aficamten
heart failure
Cytokinetics initiates trial of aficamten to treat nHCM
Clinical Trials Arena
Thu, 09/7/23 - 10:47 am
Cytokinetics
clinical trials
aficamten
non-obstructive hypertrophic cardiomyopathy
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
R&D
biotech
Merck
sotatercept
Daiichi Sankyo
AstraZeneca
Dato-DXd
Novo Nordisk
CagriSema
Eli Lilly
donanemab
Karuna Therapeutics
Zai Lab
KarXT
Moderna Therapeutics
mRNA-1647
Novartis
iptacopan
Madrigal Pharmaceuticals
resmetirom
Cytokinetics
aficamten
Roche
Chugai
tiragolumab
Unpartnered assets: on the shelf or hidden treasure?
EP Vantage
Thu, 06/15/23 - 09:54 am
R&D
ALX Oncology
Argenx
Ascendis Pharma
Cytokinetics
Karuna Therapeutics
Madrigal Pharmaceuticals
Protagonist Therapeutics
Prothena
Ultragenyx Pharmaceutical
Unique Pharma
Ventyx Biosciences
As Cytokinetics’s ALS drug fails Phase III, focus turns to cardiomyopathy candidate
Clinical Trials Arena
Mon, 04/24/23 - 11:23 am
Cytokinetics
clinical trials
ALS
reldesemtiv
cardiomyopathy
aficamten
Cytokinetics’ pipeline tumble continues after ALS med flops in phase 3 interim look
Fierce Biotech
Sun, 04/2/23 - 04:00 pm
Cytokinetics
ALS
clinical trials
reldesemtiv
FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv
Fierce Pharma
Tue, 02/28/23 - 10:51 pm
Cytokinetics
heart failure
FDA
complete response letter
Omecamtiv Mecarbil
FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use
Fierce Biotech
Tue, 12/13/22 - 11:56 pm
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug
Endpoints
Sun, 12/11/22 - 01:28 pm
FDA
Cytokinetics
heart failure
Omecamtiv Mecarbil
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics

Pages